You have made the case for a call-to-action to treat LDL-C very aggressively in diabetic patients with known ASCVD. What is your rationale for this and how do the recent rials support your recommendation to treat diabetics with ASCVD aggressively?

You have made the case for a call-to-action to treat LDL-C very aggressively in diabetic patients with known ASCVD. What is your rationale for this and how do the recent rials support your recommendation to treat diabetics with ASCVD aggressively?

You have made the case for a call-to-action to treat LDL-C very aggressively in diabetic patients with known ASCVD. What is your rationale for this and how do the recent rials support your recommendation to treat diabetics with ASCVD aggressively?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Vivian Fonseca, MD

Vivian Fonseca, MD

Professor of Medicine and Pharmacology Tullis Tulane Alumni Chair in Diabetes Chief, Section of Endocrinology Tulane University Health Sciences Center Past President, Science and Medicine American Diabetes Association